Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
Status:
Unknown status
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
Idiopathic pulmonary fibrosis(IPF) is chronic progressive fibrosing lung disease of unknown
cause. There is no effective therapy yet for this disease and the mean survival in most
reports is about 3 years after the diagnosis. Because of the stiff fibrosis of the lung,
pulmonary hypertension is the late complication of IPF and its development heralds a very
poor outcome of the patients. For the primary pulmonary hypertension, recently the effective
drugs have been available. However, there is no study about the efficacy of these drugs in
the patients with pulmonary hypertension secondary to pulmnary fibrosis, and the aim of this
trial is to study the safty and efficacy of "Iloprost," one of the safe and effective drugs
in primary pulmonary hypertension.